Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash

Overview of attention for article published in Therapeutics and Clinical Risk Management, September 2015

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 3 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 141 followers.

Lenalidomide discontinuation for rash in MDS http://t.co/062i4Bmb1E

Reply Repost Favourite

Lenalidomide discontinuation for rash in MDS http://t.co/9uxsHbkmAP

Reply Repost Favourite

Lenalidomide discontinuation for rash in MDS http://t.co/HChyEddTmV

Reply Repost Favourite